What is nference?
Founded in 2013 and headquartered in Cambridge, Massachusetts, nference operates at the intersection of machine learning and life sciences. The company provides a sophisticated software platform designed to synthesize exponentially growing biomedical knowledge. By triangulating unstructured literature with large-scale molecular and real-world evidence, nference enables researchers and clinicians to extract high-fidelity insights in real-time. This capability is essential for modern drug discovery, clinical trial optimization, and precision medicine, positioning the firm as a foundational player in the digital transformation of the pharmaceutical and healthcare sectors.
How much funding has nference raised?
nference has raised a total of $131M across 3 funding rounds:
Series A
$11M
Series B
$60M
Series C
$60M
Series A (2018): $11M with participation from Matrix Partners and Matrix Capital Management
Series B (2020): $60M led by Mayo Clinic
Series C (2020): $60M supported by Matrix Partners, Mayo Clinic Ventures, Matrix Capital Management Company, L.P., and NTTVC
Key Investors in nference
Matrix Partners
Headquartered in Chicago, Matrix Partners is an award-winning firm that specializes in pet product strategy, advertising and public relations. Passionate About PetsSM since 1987, Matrix has created successful marketing campaigns for hundreds of consumer and pet product brands.
Mayo Clinic
Mayo Clinic is a nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research. The institution is recognized for its multidisciplinary approach to patient care and medical innovation.
NTTVC
Undisclosed investor participating in the funding round.
What's next for nference?
With the recent infusion of capital, nference is well-positioned to scale its enterprise operations and expand its footprint in the global biomedical data market. The strategic focus will likely center on enhancing its neural network architecture to handle increasingly complex multi-omic datasets while deepening its integration with major healthcare providers. As the industry shifts toward data-driven decision-making, nference's ability to provide a holistic view of patient health and molecular biology will be a key differentiator. Future growth will likely involve strategic partnerships with global pharmaceutical entities and the continued refinement of its proprietary AI models to maintain its competitive edge in the rapidly evolving health-tech landscape.
See full nference company page
